{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T19:10:04Z","timestamp":1756321804081,"version":"3.44.0"},"reference-count":18,"publisher":"BMJ","issue":"6","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2019,5,24]]},"published-print":{"date-parts":[[2019,6]]},"abstract":"<jats:p>We report a case of cefepime neurotoxicity characterised by myoclonic status epilepticus with coma, in a context of acute renal failure and requiring one discontinuous conventional haemodialysis. Cefepime is a fourth-generation broad\u2010spectrum cephalosporin mainly used to treat hospital-acquired Gram-negative infections. Acute neurotoxicity is an increasingly reported adverse effect which occurs predominantly in patients with renal impairment. Renal replacement therapy has been proposed to treat this condition.<\/jats:p>","DOI":"10.1136\/bcr-2018-228108","type":"journal-article","created":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T05:35:15Z","timestamp":1559885715000},"page":"e228108","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Myoclonic status epilepticus induced by cefepime overdose requiring haemodialysis"],"prefix":"10.1136","volume":"12","author":[{"given":"Aude","family":"Garin","sequence":"first","affiliation":[{"name":"Department of Intensive Care, Centre Hospitalier Victor Jousselin, Dreux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florent","family":"Bavozet","sequence":"additional","affiliation":[{"name":"Department of Intensive Care, Centre Hospitalier Victor Jousselin, Dreux, France"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2019,6,6]]},"reference":[{"key":"2025082711425417000_12.6.e228108.1","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1186\/s13054-017-1856-1","article-title":"Cefepime-induced neurotoxicity: a systematic review","volume":"21","author":"Payne","year":"2017","journal-title":"Crit Care"},{"doi-asserted-by":"publisher","key":"2025082711425417000_12.6.e228108.2","DOI":"10.1345\/aph.1L307"},{"key":"2025082711425417000_12.6.e228108.3","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1592\/phco.26.8.1169","article-title":"Cefepime neurotoxicity: case report, pharmacokinetic considerations, and literature review","volume":"26","author":"Lam","year":"2006","journal-title":"Pharmacotherapy"},{"doi-asserted-by":"publisher","key":"2025082711425417000_12.6.e228108.4","DOI":"10.1016\/j.ijid.2003.09.003"},{"unstructured":"Cefepime [package insert]. Bristol-Myers Squibb Company, Princeton, NJ. 2016 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2012\/050679s036lbl.pdf (accessed Nov 2016).","key":"2025082711425417000_12.6.e228108.5"},{"key":"2025082711425417000_12.6.e228108.6","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.cmi.2017.01.005","article-title":"Cefepime plasma concentrations and clinical toxicity: a retrospective cohort study","volume":"23","author":"Huwyler","year":"2017","journal-title":"Clin Microbiol Infect"},{"doi-asserted-by":"publisher","key":"2025082711425417000_12.6.e228108.7","DOI":"10.1016\/S1473-3099(07)70109-3"},{"key":"2025082711425417000_12.6.e228108.8","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1186\/s13054-016-1522-z","article-title":"Not all \u03b2-lactams are equal regarding neurotoxicity","volume":"20","author":"Cha\u00efbi","year":"2016","journal-title":"Crit Care"},{"doi-asserted-by":"publisher","key":"2025082711425417000_12.6.e228108.9","DOI":"10.1186\/cc13094"},{"key":"2025082711425417000_12.6.e228108.10","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ensci.2017.08.001","article-title":"Cefepime induced neurotoxicity: A case series and review of the literature","volume":"8","author":"Isitan","year":"2017","journal-title":"eNeurologicalSci"},{"unstructured":"FDA Drug Safety Communication. Cefepime and risk of seizure in patients not receiving dosage adjustments for kidney impairment. https:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm309661.htm.","key":"2025082711425417000_12.6.e228108.11"},{"doi-asserted-by":"publisher","key":"2025082711425417000_12.6.e228108.12","DOI":"10.1128\/AAC.45.11.3148-3155.2001"},{"doi-asserted-by":"publisher","key":"2025082711425417000_12.6.e228108.13","DOI":"10.1007\/s002280050721"},{"doi-asserted-by":"publisher","key":"2025082711425417000_12.6.e228108.14","DOI":"10.1093\/jac\/dkn256"},{"doi-asserted-by":"publisher","key":"2025082711425417000_12.6.e228108.15","DOI":"10.1128\/AAC.41.11.2424"},{"key":"2025082711425417000_12.6.e228108.16","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1592\/phco.28.8.977","article-title":"An in vivo-in vitro study of cefepime and cefazolin dialytic clearance during high-flux hemodialysis","volume":"28","author":"Maynor","year":"2008","journal-title":"Pharmacotherapy"},{"doi-asserted-by":"publisher","key":"2025082711425417000_12.6.e228108.17","DOI":"10.1016\/j.clinthera.2005.05.004"},{"doi-asserted-by":"publisher","key":"2025082711425417000_12.6.e228108.18","DOI":"10.1038\/clpt.1990.149"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2018-228108","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T18:43:02Z","timestamp":1756320182000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2018-228108"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6]]},"references-count":18,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2019,6,6]]},"published-print":{"date-parts":[[2019,6]]}},"alternative-id":["10.1136\/bcr-2018-228108"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2018-228108","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2019,6]]}}}